Ladies and gentlemen, good day and welcome to Vijaya Diagnostics Limited Q2 FY25 earnings conference call hosted by Yes Securities. As a reminder, all participant lines will be in the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing the star then zero on your touch-tone phone. Please note that this conference is being recorded. I now hand the conference over to Mr. Bhavesh Gandhi from Yes Securities. Thank you, and over to you, sir.
Thank you. Good evening, everyone. This is Bhavesh here from Yes Securities. I welcome you all for the second quarter earnings conference call of Vijaya Diagnostics Limited. At the outset, I would like to thank the management for giving us this opportunity to host the call. From the management team, we have Ms. Suprita Reddy, MD and CEO, Mr. Narasimha Raju, Chief Financial Officer, and Mr. Siva Rama Raju, Head Strategy and Investor Relations. I would now hand over the call to Ms. Reddy for her opening remarks. Over to you, ma'am.
Thank you, Bhavesh, for hosting the call. Good evening and a warm welcome to everyone on the call. I will begin by presenting the key highlights for the period, after which we will take you through the operational and the financial highlights of the quarter ended 30th September 2024. I would like to begin my address on a positive note by highlighting that for the past eight consecutive quarters, we've been consistently performing better than our growth guidance. This quarter marks a significant milestone for us, with an impressive 32% year-over-year growth, of which 23% was delivered organically. This achievement reflects our confidence in our integrated business model and concept of a dense network. The encouraging part is that the growth was primarily volume-driven, with contributions coming both from our existing and newly launched centers, which are breaking even more quickly while maintaining a strong B2C share.
I'm happy to share that we have successfully transitioned our network to a new AI-powered PACS as part of our digital strategy, and this upgrade will allow us to further leverage the skill set of our specialist radiologists, improving both customer and clinician satisfaction. Additionally, it will also enable radiologists to focus on reporting cases that align with their areas of expertise and interest. I'm also happy to announce that we successfully launched operations at our hub center in Ongole. This office and the response over the first two months has been highly encouraging. We now expect the center to break even ahead of the initially anticipated timeline of two to three quarters. Additionally, we are starting operations of another state-of-the-art facility in Nizamabad tomorrow. This center is equipped with advanced technologies like a 3 Tesla MRI, CT scan, and an automated lab, and other basic radiology modalities.
We have enhanced the spoke center in Gurugram, transforming it into a fully equipped hub with the addition of an MRI and a CT machine. This upgrade allows us to offer a comprehensive range of services, from basic blood tests to advanced imaging like MRIs, all under one roof, making it on par with any other hub center that we establish in a new geography. Regarding the updates of Pune and Kolkata, we have finalized few leases across both these regions. Work is currently underway, and we expect that these centers to be operational within the next two to three quarters. As part of our expansion strategy, we have identified Bengaluru as an additional tier-one location and plan to enter this market soon through the organic route. We have been evaluating this market for the past two years, considering both inorganic and organic opportunities.
Bangalore is largely dominated by semi-branded integrated chains, each with a presence in only two to three locations across the city. Given this, we are very confident that the market holds significant potential for us, and we believe we can create a dense network in the years to come. To conclude, I would like to highlight that with a combination of a well-planned strategic expansion and the robust strength inherent in our model, we are very confident that we are well-positioned to capitalize on the growth opportunities from the ever-growing demand in this diagnostic sector. With this, I'd like to hand over to Raju to take you through the operational and the financial highlights.
Thank you, madam. Good evening and a warm welcome to everyone on the call today. I'll quickly take you through the financial performance and key developments for the current quarter and half-year ended September 30th, 2024. The consolidated revenue for the current quarter stood at INR 183 crore, reflecting a strong revenue growth rate of 32% year-on-year and 17% quarter-on-quarter. And this robust revenue growth, just like the previous quarters, was again driven by volume growth of 30% year-on-year and footfall growth of 24% year-on-year. I'm delighted to inform that the year-on-year organic growth, excluding PH Pune, is remarkable at 23%, which is the highest growth reported so far. And this strong growth is driven by volume growth of 22% and footfall growth of 18%.
I'm extremely happy to inform that the business from Hyderabad, which is a core geography with many mature centers, has grown at 18.5% year-on-year, which clearly demonstrates the strength of Vijaya's brand in a core geography. Coming to PH Pune's performance for the current quarter, the revenue is 12.2 crore, which is in line with our expectations. Coming to the geography-wide revenue contribution, Hyderabad region contributed 73%, the rest of AP Telangana was 17%, and Pune was 7%. Like the previous quarters, the revenue growth was driven by both radiology and pathology segments, reflecting the robustness of our B2C focus integrated business model. The B2C revenue stood healthy at 93%, and our radiology business stood at 35%. The revenue per test was ₹463, and revenue per patient footfall was ₹1,616 during this current quarter.
EBITDA for the current quarter stood at 76 crore, as compared to 57 crore in the corresponding quarter in the last year, reflecting a year-on-year growth rate of 33% in line with the revenue growth. Excluding PH Pune, the year-on-year growth rate in EBITDA is 24%, again in line with the revenue growth. The EBITDA margin was healthy at 41.5% in the current quarter, with an improvement of 20 basis points year-on-year and 230 basis points quarter-on-quarter. The profit after tax for the current quarter stood at 42 crore, and the PAT margin was also healthy at 23%. I will now summarize our performance for the half-year ended September 30th, 2024. The consolidated revenue is 339 crore, as against 260 crore in H1 of last year, reflecting a year-on-year growth rate of 30%. Excluding PH, the growth was 21%.
EBITDA stood healthy at INR 137 crore, as against INR 105 crore in H1 of last year, registering a year-on-year growth rate of 30%. EBITDA margin stood healthy at 40.5%, and the profit after tax was INR 74 crore, with a margin of 22%. Coming to the update on the capital investments in the current period, we have successfully started two hub centers: one in Ongole, tier two location in AP, and the second was an upgradation of spoke to hub in Gurgaon with advanced radiology equipment of MRI and CT. Considering the growing demand for oncology testing and advanced radiology, we have added a PET CT in Tirupati and a second MRI at a Kurnool geography. The company is on track of adding new centers at Pune and Kolkata through a careful expansion strategy, and this expansion will be funded from internal accruals.
To conclude, I would like to say that we continue to hold our position as the largest B2C integrated diagnostic chain, supported by a healthy balance sheet and impressive return ratios. That's all from my side. I would now request the moderator to open the line for the Q&A. Thank you.
Thank you very much. We will now begin the question and answer session. Anyone who wishes to ask a question may press star and one on their touch-tone telephone. If you wish to remove yourself from the question queue, you may press star and two. Participants are requested to use handsets while asking a question. Ladies and gentlemen, we will wait for a moment while the question queue assembles. The first question is from the line of Amey Chalke from JM Financial. Please go ahead.
Yeah, thank you for taking my question. The first question I have basically on the growth. We have delivered around 22% organic growth for the quarter. I understand it is led by seasonality, but I believe even in seasonality, this kind of growth we have not seen earlier. Does that leave some scope to increase our organic growth guidance for the year from mid-teens to towards high teens? Also, if you can explain the reasons for high volume growth apart from the PH contribution, which has delivered more than 20%. Thank you.
Yeah, so like you rightly said, there is some seasonality, but at the same time, if you see last year also, from Q1 to Q2, I think we have delivered roughly about a 15% growth, and we have delivered 17% this year. Right? And like we discussed in the earlier call, I think that's the beauty of having a dense network and also being integrated. And also, I think the shift from post-COVID, the shift from unorganized to... Like if you see the ground reality of the healthcare industry today in any of these larger markets, that could be Hyderabad, Bangalore, Delhi, Mumbai, or any other geography. So now hospitals, if you see multiple chains that are present in these geographies operating for a long time, now they are talking about creating dense networks in the geographies they are very strong. And they are all growing, right?
If there are four players in one geography, all the four players are growing. I think that's the beauty of the model. And Vijaya being known for the quality and having the talent, with the kind of efforts that we are putting and the kind of network expansion we are doing, that's where we are able to generate these volumes. The shift is happening from unorganized to organized. But coming to seasonality, it was almost like a similar quarter that we had in the last year. And on the growth guidance, Amey, like we always said, we are confident of delivering double-digit growth of, say, 15%-16%, but obviously the efforts are to achieve that growth guidance.
Sure. Sure. The second question I have is on the Gurgaon and Bangalore, both the places we are showing our intent to grow presence organically. So if you can elaborate on our plans in both these regions for the next two to three years, and also as you grow in these other regions, the new regions, do you expect to deliver similar profitability? Thank you, and I will join that.
So Amey, Gurgaon is an old center. Like we told you, it was a center that we tried out a long time ago. I don't remember the exact time. It's a wellness concept, and it's a large center with almost about 12,000 area footprint. And since we are integrated in all of our other centers, and this center was the only center up north doing only wellness, and we had the space available, we wanted to upgrade it and bring it to the level of any of our more sophisticated and updated centers in terms of technology. And that is the reason why we have made sure that it is also integrated, and it's been a mature center now.
We see a lot of repeat customers coming back to that center, and that's the reason why we wanted to make it more whole and fulfilled in terms of a customer experience itself. And in terms of expansion in Gurgaon, immediately we do not have any plans of doing that. But when it comes to Bangalore, like we mentioned, being dominant in the south, the largest player in the south, and the three top cities probably known for their healthcare are Chennai, Bangalore, and Hyderabad.
Now that we have other centers and the concentration of business from Hyderabad coming to its 70s, we said we have more room to explore new markets, and that's the reason why we were able to probably give some time to this market, understand this market, and we feel that just like Kolkata, we'll be able to grow the dense network in this particular city. It's a tier-one city, and the wellness and the integrated business make sense to us. Like I mentioned in the speech, there are a lot of chains there. Integrated is not new to Bengaluru, and they're all two to five center chains. So we said there's more than enough room to grow, and we would like to take up that route organically rather than inorganically. That's not something that we would probably say we'll do about five centers in one year.
It's over a period of time that we would like to invest and make sure Bangalore is a good market for us to grow in.
Sure. Sure. Thank you so much.
Thank you.
Thank you. The next question is from the line of Anshul from Emkay Global. Please go ahead.
Hi. Thank you for the opportunity. My first question is on the samples per patient. Now, this metric is growing 25% plus in the last three quarters now. Is wellness the only reason driving this samples per patient number? And how sustainable is this growth number? Do we see this settling over here? Awareness is only 13% of our business. Again, do we see that also growing?
Yeah. So Anshul, so basically, if you see pre-PH, right, we were at somewhere around 3.3. The comparison that we are seeing is like last year we were only Vijaya and now Vijaya with PH. And PH has got three hub centers and three spoke centers, right, where you see the higher test for footfall at a hub center. So that's the major reason why you are seeing the change. I think more or less from now that test for footfall should be somewhere around 3.4 to 3.5. So it all depends on the combination of hubs and spokes. Like if you have two years of a period where you'll open more hubs, you may see that growing. And whenever you add up spokes, you see that getting diluted. It all depends on the mix of the centers. Wellness, to a certain extent, yes.
Earlier we were at 10%, 11%, now 13%. But otherwise, we don't see major change in tests per footfall going forward.
Okay. Any specific plans for growing the wellness business?
Not specifically. Anshul, like we mentioned, wellness has been part and parcel of the history of Vijaya. We've always been doing it. It's integrated. So a package is more meaningful because it will involve some amount of radiology and pathology, just not fast work. So we don't make a conscious effort, but it's also sometimes just like your fevers are seasonal, even health and wellness is seasonal. So you see an up and down, but more or less it will remain in that 13-14, which is what we think is an achievable number. We don't try and upsell packages in Vijaya. So it's somebody who comes in, walks in with a need or a want of getting a wellness package done who is the one we actually serve.
Got it. My second question is on our CapEx guidance, which we are given post the Q4 results of about 220-odd crores, 230-odd crores in the next two years. Does that whole step, considering that you have just done 40 crores of CapEx in H1, will it be more back-ended? How many hubs are we planning to commission in FY25 itself?
So Anshul, as we communicated in the previous calls, okay, we are planning to add at least like 10-12 hubs across these two financial years. Out of that, already two hubs are already ready, like one we already launched, Ongole. Okay? And the other one is ready tomorrow at Nizamabad, okay, similar hub center in a larger area. Okay? So another 10 more centers apart from these two hubs will get opened in these two financial years, FY25 and FY26. So the CapEx guidance of approximately like INR 200 crore on these new centers remains the same. And in the first six months, as you rightly told, the CapEx on the new centers was approximately like INR 40 crore.
Got it, so I believe we had initially given a guidance of 10 centers in the next two years, but we are upping it to probably 12 centers. My question is, our internal accruals or cash flow generation seems very robust. Would we be able to add Bangalore in this by somewhere in FY26 itself? Can we go slightly more aggressive on this hub expansion, considering our balance sheet is supporting it? We are seeing incremental signs of organic growth coming in as well for our tested model.
Absolutely. Anshul, like we mentioned, it's not the CapEx that drives us to grow. It's the geography, the interest, and then probably also the people. So like I've mentioned, we will be looking at Bangalore. We don't have anything concrete for me to confirm on this call today, but definitely if something comes up, you will be seeing a few centers coming up in this region by FY26.
Sure. Many thanks for your time. All the very best for the remainder of the year.
Thanks, Anshul.
Thank you. The next question is from the line of Sumit Gupta from Centrum Broking Limited. Please go ahead.
Hey, hi. Thank you for the opportunity. Am I audible?
Yeah, you're audible.
Yes, sir, so what are the PH margins for this quarter?
Sorry? 40%, Sumit.
40?
Yeah, yeah. Yeah, yeah. For the PH margins?
Yeah, yeah, PH margins.
Yeah, yeah. So going forward also, so on the standalone basis, it comes out around 41.5%-42%. So going forward also in the second half, how do you see it panning out on the standalone basis? So if you see the 41.5% is at the consolidated level, Sumit. Okay? So since we are adding new centers, okay, like in Pune also, a few centers, the work is happening. So as we mentioned earlier, in any one quarter, say, for example, two or three major hubs get opened, say, for example, like a Q4, okay, or a Q1. So in those quarters, there might be a slight drag because of these new centers because they take typically these hubs take at least like in outside geographies, they take at least like three quarters for breakeven.
So because of that, if two or three hubs get opened in a similar period, that quarter margins might be like 1% or 2% here and there, okay, impact might be there. But what I look at it is, okay, for a full financial year, I'm fairly confident that 40% EBITDA margins will be maintained.
Okay. So, point one, I want to understand more about 40% EBITDA. Is it strong operating leverage is likely to play out? So, can that be surpassing 40% guidance? Just want to understand on that aspect. Strong operating leverage is getting played out. However, obviously, there are some new additions. But what I see is those will not be able to offset the strong leverage that the existing centers will do. So just want to understand on that part.
So definitely the operating leverage plays out, okay, that's the reason why you see the improvement in the EBITDA margins. Okay? Like almost close to like a 230 basis points improvement is there from Q1 to Q2, definitely because of the fixed cost operating leverage play. And as you know, we continue to invest, okay, in technology, okay, digital marketing. Okay? So continuous efforts are there, okay, to invest in various channels. So that's the reason. Apart from that, okay, on account of these hubs also, even though if there is a drag, is there like a 1% and 2%, okay, I expect that the operating leverage play, okay, might take care of that. And then on a sustainable basis, okay, what I'm fairly confident is this 40% EBITDA margins will be achievable.
Okay. Great. And so Gulbarga has breakeven?
Sorry?
Gulbarga facility.
Gulbarga, this month we are going to complete one year. This is one center which took us four quarters. Like the guidance was three-to-four quarters. This center took us four quarters. Generally, how we announce breakeven is we'll wait out and look for another one-to-two months and then announce the breakeven. Yes, Gulbarga is going to breakeven this month.
Okay, lastly on the CapEx side, sorry for the repeat. So you guided for INR 200 crore, right?
200 crore, approximately like 10 hubs spanning across these two financial years, Sumit.
Okay. Okay. So out of this, how much is the equipment?
So equipment accounts to approximately like 75% is equipment, okay? And then the rest is towards the infrastructure, plant and machinery others, and then you have the software, computers, etc. But the main radiology equipment accounts for almost close to 75%.
Understood. Thank you.
Thank you.
Thank you. The next question is from the line of Abdulkader Puranwala from ICICI Securities. Please go ahead.
Yeah. Hi. Thank you for the opportunity. So just wanted to understand your thought process of entering into Bangalore and then the expansion in Gurgaon. So what I understand is basically the healthcare market of these two cities are much different as compared to where you are currently present in two. So just if you could share your strategic rationale for selecting these two cities and considering the network hospitals which are located in these two cities, those are quite having an integrated diagnostic model. So how do we compete against those? And in terms of breakeven, when you're talking about a three-quarters breakeven for your traditional hubs, do you see similar kind of a breakeven model to happen here as well?
So in the past, like in the over many calls when we were asked, "Why don't you open 15, 20, or 25 centers in a year?" It was always not about the capital. It was about the people, right? So basically, we said we are comfortable opening 15 centers a year. It's because this business, the key for success is the team, right, which we have realized very early. And from past two to three years, what we were doing is let's take any market. Even today when we acquired Pune or when we launched Kolkata, from past two to three years, we are trying to identify people within the company and also we are getting talent from mid-level to senior level, right, across core departments like operations, sales, projects, because these are the key departments for our success of the business, right? And we are training them internally, right?
It's always the bandwidth which will allow us to grow. Ten years back, I think we were comfortable launching two centers and launching markets within Andhra, Telangana. Five years back, we thought we were comfortable launching West Bengal. Then two years back, we thought we were comfortable doing one acquisition. Today, with the kind of bandwidth and the team that we have, we are comfortable launching one more market. While choosing the market, right? Today if you take India, it can be any state capital, right? I think integrated play is at a very initial stage. You have very few players, like I think hardly very few players who have got that network in integrated play, but which is very required. Again, in Bangalore, if you see, there are multiple integrated players operating in each of these micro markets.
So again, comparing this to a hospital, so I think this model works well where you have a very good doctor strength, right? When you have a lot of super specialty hospitals is where you have the super specialty doctors. I think no other market today has the highest density than Hyderabad. And if you are able to compete in Hyderabad with any of these hospitals and able to make INR 480 crores of revenue per year, we don't see any challenge in getting into Bangalore market. And again, Bangalore is a developed market. Like ma'am said, right, Bangalore, Chennai, Hyderabad, these markets are known for healthcare facilities from a long time. So out of the options available, we thought Bangalore is a market which will be feasible for us. And we also have people within the team who can take care of this market.
Abdul, just to answer your question, it's not every geography is unique. So if you say Andhra and Telangana, Hyderabad might work differently versus the Rajahmundry center or a Karimnagar in Telangana itself. So when we try to push ourselves out of the comfort zone and when you're trying to probably replicate what you're good at and mastered over the last 40 years, I don't think whether it's Chennai or Bangalore or Kolkata makes a difference. I think the difference comes in probably four quarters or five quarters of breakeven. But the confidence of absolutely breaking even and making that center a success is what probably allows all of us to look at a new geography and confidently move on and take that step forward, and that's exactly what we did in the east.
And if we took almost six years when we took a loss-making company, we acquired it. It took us a long time to clean it up, break it even. In spite of that, we said we will try and we will grow in the east. And we started the VIP Road Center. And if that could do well, I think that's also a booster. And probably to say you're out of your comfort zone doesn't matter where you are as long as you have a customer base that understands you, educated, there's affordability. And that's probably working well for us. So I don't know, maybe five quarters from now, I might say we'll go into Chennai too. But today we're saying we'll want to try Bangalore.
Yeah. And I appreciate that confidence. Just on the hub centers that you opened, so when we talk about an integrated model, so I mean, on day one, do we introduce the entire offering that is both pathology or radiology or?
Definitely, Abdulkader. So how we operate is we do not do it phase-wise. When a center opens, that's also why we need that incubation period of 90, almost 120 days, because you will have that center that will open up to a customer right from a complete urine exam to an MRI, three Tesla, or in certain cases, even a PET CT. So if you looked at Tirupati, we added a PET because we saw the response. But on day one, it was a fully automated lab with an ultrasound, TMT, Mammo, all the way up to a three Tesla MRI. And it'll be the same tomorrow in the center that we're opening in Nizamabad. That will offer an MR, that will offer high-end cardiac imaging, and will offer lab facilities all in one go.
And also, to answer a question asked by someone else previously, what happens is when we open hubs in regions outside of the core geography, even though there's leverage, what happens is we tend to take on staff to be able to train them and get them ready to operate the center. So that cost gets added a little bit, but that will probably play out in the quarters to come, the second quarter. But you are prepared on day one to be able to do any of these tests in that particular center itself.
Got it. Thank you for answering my question. I'll go and back again. Thank you.
Thank you.
Thank you. The next question is from the line of Rishi Mody from Mercurus Investment Managers. Please go ahead.
Hi, guys, can you hear me?
Yeah. Yeah. Yeah, Rishi. Yes, Rishi.
Yeah. Hi. So just on the gross margin front, right? We've seen a dip in this quarter. Is it something structural? Is it a one-off? Because normally what we've seen in other diagnostic companies is that as your packages business increases, your gross margin is increasing for at least the path players. So just wanted to understand, is that not the case for us?
Sure, Rishi. Raju here. As you said, okay, the material consumption has slightly moved up, okay, year on year from 11.8% to 12.6%. Okay? It's a combination of three factors. One is the test mix, and the second one is depends upon the pathology radiology mix. As you know, radiology has slightly lower material consumption compared to pathology. And if you look at the growth in this current quarter, okay, on a standalone level, excluding PH, you have seen 23% growth. Okay? So across these two segments, the growth is there, but there's a slightly higher growth is there on the pathology segment. I remember like, okay, 24 or 25% growth is there on the pathology front. Okay? I think like a 2% lower number is there in the radiology. So the moment you have more pathology revenue, slightly the consumption will go up.
The third point is the wellness. Okay? Whenever the wellness segment goes up, slightly there is an impact on the material consumption by a few basis points. So if you look at it in this current year, it is 13.7%. Okay? Slightly increase is there as compared to the last year. Approximately in this current year, excluding P.H., we've done INR 22.5 crore wellness. Okay? So it's a combination of these three factors, Rishi. That's the reason why there's a movement from 11.8% to slightly to 12.6%. But what we have generally budgeted and then communicated is that generally it ranges between 12%-12.5%. And this was the case, Rishi, even in the past years. I think in the previous years also, you've seen that gross margins moving by points or 50 basis points between the quarters.
Okay, so just wanted to follow up there because Dr. Lal in the recent call, right, they said that their packages business has become gross margin accretive for them. They have been expanding the gross margin for the last few quarters. So, just, I know you're saying that the packages business is gross margin diluted. So just wanted to understand where is the gap in my understanding.
So Rishi, it depends, right? So for example, if we are at, say, 13.7% today, and if you are at that level and still growing at a higher percentage, then with volumes, you may see the gross margin, you may getting some advantage on gross margin. And also if you do price increases, right, is when also you'll see some for the same package, if we increase the price, right, you'll see some gross margin addition there. But in the last two to three years, we have not taken any price increases except that 1%-2% at a broad level for a few tests which we have done. So that's one of the reasons why you've not seen the gross margin improving. I think this is a combination generally packages, at least for VGR, gross margin dilutive and a bit accretive, right?
But if you generally take the price increase, it's when you see the gross margin moving.
Okay. All right. Got it. Second, I see that you've given the guidance on the hub addition. Any guidance on spoke addition over the next couple of years?
Rishi, again, as we are focusing on these new markets like Pune, Kolkata, and then Bangalore, right? And in Pune also, we have signed one and we are also looking for a few more spokes, right? But I think these two years, FY 25 and 26, you will see more of hubs. And then the subsequent years, you'll see more of spokes coming in. And Rishi, one spoke, the work is almost completed in Pune. We're just waiting for approval. I think we might receive the approvals in this month, so we might launch it in December month. So the idea is once these hubs are getting established, right, simultaneously, the work will start in terms of the spokes.
Right. I understand the bandwidth being used up for the hubs in the new geographies, but utilizing the hubs that we have invested in the last year, which is like the Tirupati one, Rajahmundry one, and through spoke investments in those regions, is that going to happen or we don't have the bandwidth for that right now?
Rishi, it's not about the bandwidth. It's also about looking at the concentration of people in and around that 150-200 kilometers. When you have some amount, if you look at Rajahmundry as a market, you still have a lot of development going on in terms of probably large high-rise buildings and society kind of residential complexes, right? Until an analyst that comes in, your spoke won't play out because the spokes generally bring in business that is more into pathology and also tests that require fasting. Until housing develops in that particular area, probably going and putting in a spoke is not going to play out as expected. Even though when we see that happening, we would not back out. It's not about the bandwidth. All of these geographies that we have mentioned have a different team working on them. It's not just a Hyderabad-based team.
We have a separate team that's sitting in Kolkata overlooking the Kolkata expansion, likewise in Pune. It's not about that. It's just about these tier two places playing out and that residential, the visibility that you would see in a metro city coming up there is what we're waiting for. We see that coming. You will see a spoke getting added there immediately.
Just to add, Rishi, see, and also these centers are not yet mature. For example, if you take Kurnool, right, we have one hub with five spokes in that geography, right? So Rajahmundry, Tirupati are still growing. These centers have not hit that maturity. So maybe I think one, two years down the line is when you will start seeing spokes coming in these geographies.
Okay. Got it. Last, just wanted to understand, now we are entering, we are focusing on four new geographies outside of AP Telangana. We've got Pune, we've got Kolkata, and now we're entering Bangalore and maybe even increasing our interest in Gurgaon. So just wanted to understand, firstly, you did mention for store openings, you have the bandwidth, but in terms of operational bandwidth, do we have that or are we going to rely on external talent?
In our B2C business, the more the number of executives, the better the experience. So if you ask me, probably your mid-level to the senior mid-level is what basically empowers us to do that. So that is a level that we've invested in in the last two-to-three years. You would have seen if we had four or five cluster managers, would have become 14-15 cluster managers, multiple AVP operations, multiple GMs. So those roles are increasing. Probably we just don't voice them out, but those are the ones who actually make sure the operations run at what we would want to on ground zero.
And that's the reason why we are confident that we'll be able to do that both in Pune and Kolkata because that's the size of the team that we're investing in, training in, and those are the ones who actually run the show in those geographies. So I don't think I don't look at that as a challenge. But yes, finding the right set of people, like you know and like everyone else knows, is a challenge today. And when we see that opportunity, we do not let it go by. Gurgaon, we absolutely have no interest in expanding. Like I've mentioned to you, it's an old center, the only center in the network which did not have high-end imaging.
A lot of time, the teams also said, "Why the stepmotherly treatment?" And that's the only reason why we said, "Let's actually, it's been quite some time, give it a revamp, make it look better, invest in some technology, and make it probably to a level of what we would call a VGR diagnostic down south in Gurugram too." So that's not something that we should be looking at as interest of growth, but definitely, yes, Bengaluru, Pune, and Kolkata is what we're investing in.
All right. Okay. That's helpful. Thank you. Thank you, guys. All the best.
Thanks, Rishi.
The next question is in the line of Dheeraj and Individual Investor. Please go ahead.
Hello?
Yes, sir. Please go ahead.
Yes. My voice is audible to you?
Yes, Dheeraj.
Yeah. Actually, I wanted to know how much is the percentage of outsourced diagnostics you are giving to others?
I think it would be less than 0.5% of our total revenue.
0.3% also maybe.
And what is the major steps are you taking to reduce the consumption percentage?
Which consumption, Dheeraj?
Consumption margin, gross margin. Consumption cost.
So, Dheeraj, currently the gross margins of the company are at 87%-88%, which are already the industry-leading margins, okay, for us as compared to any other peer group. The couple of reasons why we are able to enjoy these industry-leading gross margins in the range of 87%-88%. One is the dominant share of revenue coming from B2C segment where we're enjoying the full MRP. And the second thing is we're having the integrated diagnostic facilities across our network. And also our cost structure is also efficient. Okay? Since we are a market leader, we're able to enjoy the better reagent material pricing, better pricing on the billings for the radiology, etc. So as we're enjoying these industry-leading margins, so going forward as well, it will be in the range of that 87%-88% gross margin.
More than I want to know is percentage of B2C and B2B business which we are getting?
95% to 96% will be B2C, and probably 3% to 4% will be B2B. We are a B2C-driven company, Dheeraj.
Yeah. It's a very good number we have.
And one more thing, when are you starting the business in Nizamabad?
Tomorrow morning.
What is the CapEx cost has been incurred in Nizamabad to open it?
One second. I'll let Raju answer that.
Approximately INR 14-15 crore, Dheeraj. I don't have the exact number, but it is in this range. Because we are going to invest in a good technology, the high-end 3 Tesla MRI we're investing, okay, and also a high-end CT scan machine we're investing. Also all the basic radiology modalities will be there. With a very good infrastructure built on almost close to 8,000-9,000 sq ft facility.
How much is the bank borrowing of it?
We don't have any bank borrowings as of now. We're a debt-free company. And the surplus cash balance is approximately INR 225 crore.
Okay. Thank you so much.
Thank you.
Thank you. Thanks, Dheeraj. Thank you.
The next question is from the line of Pranav Chawla from Antique Stock Broking. Please go ahead.
Good evening, sir. Congratulations on the great set of results. So I was just going through your presentation. Can you just elaborate why Kolkata has been so lumpy for us? If I see the revenue in the previous quarter was around INR 6 crores, now it has fallen down to under INR 5 crores. Any particular reason?
Yeah. That's.
On a sequential basis.
Yeah. Yeah. So basically, I think every one of us are aware, right? So we had some unfortunate events in Kolkata in Q2. Because of that, there were multiple strikes. And even because of this Bangladesh issue, for some time, that market has suffered. So that's the only reason why almost for 20-25 days, the business got hit in this market. Otherwise, specifically, if you see the VIP Road Center, it's still growing. We had a very good October, and even the current November month ramp up is picking up well.
Got it. So does this impact our future plans for Kolkata in the near term? If I'm not mistaken, we have one more hub coming up in the fourth quarter.
No, nothing. So I think these are all more of temporary issues. So in fact, we have signed more leases in Kolkata. You'll only see the center addition happening in the next one, two years. More centers coming in the next one, two years.
Got it. And sir, any update on Medinova integration? Are we reaping benefits of this in this quarter or they're yet to come?
So the formal merger process approvals are pending as of now. Okay? We have received a few points from the stock exchange because both are listed companies, right? So we need to get the clearance from the stock exchanges and SEBI first, which was supposed to be received last month, but there is some delay from the authority side. So once we get those approvals, then petition will be moved to the NCLT. Then from there, the process will take at least like five to six months, okay, because there will be shareholders' approval, etc. So we expect the whole process might get completed sometime around May or June month.
Okay. And one last question, if you may allow, is primarily what is driving our Hyderabad market growth? Because I think for the past couple of years, we haven't been able to grow at this 18-odd% rate. Suddenly, we are at 18-20% growth rate for this market. Any particular reason for it?
I think even in the past years, we were growing in double digit. Like we said in the earlier calls, we've added a very good capacity from FY 2019 to 2023. In between, because of COVID, these centers took time to ramp up. Apart from that, the best part here for us is that both the existing and the new centers are performing, right? Like we said, it's a B2C brand. We are seeing the direct walk-ins growing. I think it's because of the capacity and the dense network that we have. We are able to see this kind of a growth. Otherwise, even in the past years, we were growing at, say, 12%-14%.
What would be our market share in Hyderabad?
So this market size is slightly tricky if we have to get the exact numbers because different companies give different numbers. But understanding the market, what we guess is that will be less than, say, 20% of the diagnostic market. That's again, guess based on multiple factors that we know in the market. But to be very frank, we don't have the exact number.
What is the contribution of flagship centers?
So flagship generates roughly around INR 60 crores, so INR 5 crores per month, right? I think at the current run rate, I think at the time of IPO, it was roughly around 15% was the contribution. Today, I think it's about 10% of our monthly, less than 10% of our monthly revenue.
Okay. Got it. Thank you so much, sir. I'll get back to the team.
Thank you. The next question is from the line of Devang from Marcellus Investment Managers. Please go ahead.
Yes. Raju, what's the Ind AS 116 impact on EBITDA and PBT for Q2?
Dev, Ind AS EBITDA at the PAT level, it's approximately INR 1.6 crore for this current quarter, which is like 0.9%. The PAT margins would have been higher by 0.9%. In the current quarter, we reported 23%. Had we followed Indian GAAP, it would have become 23.90%. In absolute number, it's approximately INR 1.6 crore for the current quarter.
Okay. Okay. Got it. And secondly, so in your opening remarks, you mentioned that your transition to some AI-powered PACS for your entire network. So can you elaborate a bit more on this? What exactly is this and what sort of benefits do we expect from this?
Like we said, we have a large team of more than 200-250 radiologists who work across all these centers.
Devang. Devang.
So the thing is, when we have a large team, their expertise and their interest differs into different modalities. And what this AI PACS basically does is connects all of our doctors, plus also assigns cases depending on the skill set of these doctors, which creates a more specialized expertise report, even to the customer's beneficial because if we have pediatric radiologists, then what will happen is all the pediatric radiology cases get assigned to these pediatric radiologists. Like a cardiac case will only get assigned to a radiologist who's subspecialized in cardiology. Two things happen. One is we'll be able to churn out a report much faster, and this will be of the highest quality because you are actually investing in a doctor who's specialized in that submodality reporting this case. And this entire system is based on a web-based platform. It has AI capabilities.
It basically lets the doctor know whatever information he needs to know before. It's a first-come, first-served software. The TAT is monitored automatically instead of us intervening manually to do that. It's basically to enhance the entire customer experience and keep the reporting at the highest quality possible.
Okay. Throughput per radiologist will increase because of this.
It will also increase and will also make sure that there's no attrition in the radiology base because they tend to do various cases and also what they enjoy at the same time.
Right. And if throughput increases, do we also then see some benefits in professional fees that we pay to radiologists?
So we have different models of our professionals working with us. We have people who come in for a few hours versus eight hours, a few people who come in on target models. So it completely depends on various models that a consultant wants to come in.
Many of these doctors where the throughput is high, generally they're on incentive models. Basically, the more scans they report, the more they earn. I don't think it will get any benefit on professional fee front. It's more on.
The productivity front and the experience front and probably the professional satisfaction for the consultant himself.
Okay. Okay. Got it. Thank you.
Yeah. Customer responsibility.
Thank you. The next question is from the line of Anshul from Emkay Global . Please go ahead.
Thank you for the follow-up opportunity. If you could just, I think you've been a very strong position to guide us about how many hubs can be commissioned in Pune and Kolkata in H2 FY25?
Anshul, so I think in this year, we have already opened two hubs, right? Rather than naming the region, because these depends on multiple things, right? The landlords giving us on time and the work happening on time, all that. We would say we'll open about six hubs, at least six hubs in this year. We're already going to open two hubs, right? And we have upgraded one more hub in Gurgaon, right? Other than this, you'll see another three to four hubs across, it can be any region, across these regions coming up in this year, or maybe early Q1 FY26.
Okay. So in total, about four more hubs till probably Q1 FY26. Would that be correct?
Yeah. Correct.
Great. And our guidance of breaking even in these hubs outside our core geography of about three-to-four quarters remains the same?
Yes. Three to four quarters. Yes.
And if I heard ma'am correctly, during our opening remarks, she said the ongoing hub will break even within two to three quarters itself?
Yeah. We'll be able to break even within two to three quarters, less than two to three quarters.
Okay. Many thanks. Many thanks. Thank you.
Thanks, Anshul.
Thank you. The next question is from the line of Dheeraj, an individual investor. Please go ahead. Dheeraj, your line has been unmuted. Please go ahead with your question.
Hello.
Hello?
Hello?
We can hear you.
Yeah. S orry to ask you one more question. Are you planning to split the shares in future or planning to issue bonus shares?
Hi, Dheeraj. Currently, there are no such plans, but if anything, relating to the share capital reorganization, it will be with the board of directors. Currently, there are no such plans.
Okay. Thank you so much.
Thank you.
Thank you. The next question is from the line of Bhavesh Gandhi from Yes Securities. Please go ahead.
Yeah. One question from my side on the Bangalore plan. So you mentioned that there are two to five kind of integrated chains operating in Bangalore, and it's not a new concept to the city. And you have also mentioned about becoming organic. So in any thought, why inorganic would not have made sense? I mean, what were the reasons that you found since you have been observing the market for two years?
So, Bhavesh, we have evaluated both the options, and then we felt organic route will create a better work better for us, both in terms of financials and also rather than taking somebody with three to four centers who are operating in micro market, we want to open more centers across the city with the brand new centers, and then that will also make financially viable.
Bhavesh, it's not that we did not look at the inorganic route. Just the way that we looked at Pune, we also invested a lot of time into looking at a lot of opportunities that came our way in the entire southern region, but there are a few things that, like we always tell you, in an inorganic opportunity, we look at probably the mindset, the wavelength, the compatibility between both the businesses running, whether it's a B2C business or a B2B business, or were there only radiology-focused centers where probably their government work was more. A lot of reasons that probably we did not think added value, and that is the reason why we did not take that route.
And the second one was pricing, which we always have to make sure that the investors' money is also looked at when we go and we try to invest into an opportunity where it does not make sense to us. And when we invested about two years of our time and looked at the market in multiple opportunities like this, that we had more than enough knowledge to go the organic route, that there's no hurry. We'll take our time out, but we'll probably build it out organically. That's the only reason. There's no other reason. Even now, if there's something that comes up our way which interests us in that particular region, we will definitely look at it. We will not say that we are going the organic route, so we're not going to take that.
But I think the priority here is whether both the businesses will work seamlessly together.
Got it. Got it. That's it from my side.
Sure. Thank you.
Thank you. As there are no further questions from the participants, I now hand the conference over to the management for their closing comments.
I thank everyone for joining this call today. For any information or clarifications, we would love to answer you. You can get in touch with us. Thank you, everyone.
On behalf of Yes Securities, that concludes this conference. Thank you for joining us, and you may now disconnect your lines.
Thank you.